The IUSG is a charitable organisation under section 501(c)3 of the US Internal Revenue Service code. The 1023 application and 990 forms for 2013-2017 are available upon request to Prof. Vishali Gupta, Secretary IUSG.





The IUSG was formed in 1978 by a small number of clinicians who shared a common interest in uveitis. Over the next almost 40 years the group has increased in size to over 100 uveitis specialists from all over the world.

The IUSG comprises clinicians and researchers who are committed to stimulate, encourage, and intensify a converted effort in research and clinical management of uveitis, with the goal of developing new methods for the diagnosis, treatment, and prevention of the blinding complications of uveitis. 

The IUSG is a member of the International Federation of Ophthalmological Societies (IFOS); the Executive Body of IFOS is the International Council of Ophthalmology (ICO).

IUSG Officers

President: Manfred Zierhut
Secretary: Vishali Gupta
Treasurer: Marc de Smet
(Immediate Past President: Janet Davis)

Manfred Zierhut
Vishali Gupta
Mark de Smet
Show More


IUSG participation at international meetings



Accra, Ghana. February  8-14, 2020.

For more information and registration click here.

Download the flyer here.


Singapore. July 11 - 14, 2020 (more information to follow).

Current Membership Application Guidelines

There are three categories of membership: Active, Associate and Honorary.

Active Membership

Membership applications are welcomed from clinicians whose practice focuses primarily on uveitis.  Researchers in ocular inflammation and uveitis will also be considered:

  • In the case of ophthalmologists, consultant practice centered on uveitis for a minimum of five years, following completion of a fellowship. In the case of scientists, 5 years of research in a field related to uveitis after completion of a PhD or completion of a post-doctoral fellowship in a uveitis related field

  • Please submit:

  1. A list of your peer-reviewed published papers, of which a minimum of 10 must be in the subspecialty of uveitis.

  2. Please highlight 5 publications on uveitis where you are the first or senior author and include the Impact Factor of each journal. It is acceptable to replace a maximum of 1 publication with 2 Case Reports i.e. 4 publications and 2 Case Reports. 

  • Presentation of a scientific paper at an IUSG meeting is encouraged but not essential.

  • Two letters of recommendation from IUSG members. One letter coming preferably from the same country as the candidate (alternatively, a member who has good knowledge of the candidate’s practice of uveitis or knowledge of his/her uveitis related research).

  • Up-to-date curriculum vitae.

  • A letter expressing interest in joining the IUSG.


Associate Membership

  • Clinical practice involving uveitis for a minimum of five years (not including any time spent as a Fellow).

  • Uveitis should form at least 20% of their clinical practice, and they should be recognized in their country as a referral specialist for uveitis.

  • Ten publications related to uveitis.  

  • Should be permanently living in a developing/emerging country. As proposed by the credentials sub-committee and approved by the general assembly.

  • Two supporting letters from IUSG members, one of who should have personal knowledge of the candidate's practice of uveitis.

  • Up-to-date curriculum vitae.

  • A letter expressing interest in joining the IUSG.

Honorary Membership

By invitation only

The Credentials sub-Committee screens applications and informs candidates if they are not currently competitive with other applicants and should wait to apply.

To facilitate review, all applicants are requested to make a single digital file beginning with the letter of intent, CV, letters of recommendation, and ending with pdfs or scans of their 10‐20 best publications in uveitis.

Those candidates fulfilling the above guidelines will be recommended to the rest of the IUSG members for membership acceptance. If after three weeks the IUSG members have not expressed any concerns the candidate will then be automatically accepted as a member. There will be no requirement to present for membership but newly elected members will be encouraged to give a presentation at a future IUSG meeting. An unsuccessful application should not deter candidates from applying for membership in the future. 

Applications should be submitted by email to Prof. Vishali Gupta, Honorary Secretary IUSG (





Uveitis is a name given to inflammation inside the eye that in some patients can lead to blindness. It can affect one or both eyes and the inflammation involves the uveal tract (iris, ciliary body, and choroid), although inflammation of adjacent tissues, such as vitreous humour, retina, and optic nerve also occurs. 

Little is known about the causes of uveitis, but in cases of endogenous uveitis in which no link with an infectious agent can be identified, abnormalities of immune regulation have been invoked as the cause. Many cases are often labelled as idiopathic, but in some they may be part of systemic disease process, such as sarcoidosis, multiple sclerosis, and Behçet’s disease, or associated with the HLA-B27 positive group of diseases. Infectious agents, such as the herpes group of viruses, toxoplasma gondii, mycobacterium tuberculosis, and treponema pallidum are also well-recognised causes. 

The incidence of uveitis varies from 14 to 52.4/100,000 with the overall prevalence around the world up to 0.73%. In about half the patients the age of onset is in the third or fourth decade of life, so they are presenting at an age where they are in the most active period of their working life. This age distribution makes uveitis a group of ocular diseases with an important socioeconomic impact. There is a specific sub-group in children that is associated with juvenile idiopathic arthritis.

Many cases will resolve rapidly, some may have repeated attacks in one or both eyes, but a significant number of patients develop persistent disease with inflammatory damage to ocular structures resulting in severe visual impairment. The main causes of sight loss are cystoid macular edema, cataract, and glaucoma.

Approximately 5-20% of legal blindness in developed countries is due to uveitis, and it has been estimated that uveitis accounts for 10-15% of all cases of total blindness in the USA. Acute anterior uveitis is the commonest subtype and carries the best visual outcome, with a worse visual prognosis seen in patients with posterior uveitis and panuveitis where the back of the eye is involved.

In non-infectious causes, therapy is usually aimed at dampening down the immune response with corticosteroids being the first line treatment. For anterior uveitis eye drops are often the mainstay of treatment, but in sight threatening disease corticosteroid tablets then immunosuppressive agents and biologics may be required to improve or preserve sight.



Ocular Immunology and Inflammation is the official journal of the International Uveitis Study Group.

It is published by Taylor & Francis and the Editor is Manfred Zierhut. The current issue can be viewed here.

IUSG Members who are up-to-date with their Membership Dues have online access to the journal. 


Mark de Smet